Explaining the need to improve the outcome of 1L DLBCL treatment
Key efficacy data from the POLARIX trial explained
See how the safety profile of Pola-R-CHP compares to R-CHOP
Explaining the need to improve the outcome of 1L DLBCL treatment
Key efficacy data from the POLARIX trial explained
See how the safety profile of Pola-R-CHP compares to R-CHOP
Get an overview of the clinical trial design and primary endpoint of POLARIX
An expert’s view on how in DLBCL, 1L treatment represents the best chance of a successful outcome
References: 1. Tilly H, et al. N Engl J Med. 2022;386:351-63. 2. Elstrom RL, et al. Clin Lymphoma Myeloma Leuk. 2010;10:192-6. 3. Purdum A, et al. Oncologist. 2019;24:1229-36. 4. Vitolo U, et al. J Clin Oncol. 2017;35:3529-37. 5. Harkins RA, et al. Expert Rev Pharmacoecon Outcomes Res. 2019;19:645-61. 6. Maurer MJ, et al. J Clin Oncol. 2014;32:1066-73. 7. Maurer MJ, et al. Ann Oncol. 2018;29:1822-7.
Key efficacy data from the POLARIX trial explained
An expert’s view on how in DLBCL, 1L treatment represents the best chance of a successful outcome
References: 1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
An expert’s view on how in DLBCL, 1L treatment represents the best chance of a successful outcome
See how the safety profile of Pola-R-CHP compares to R-CHOP
References: 1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
See how the safety profile of Pola-R-CHP compares to R-CHOP
Learn about the relevance of PFS data for predicting long-term patient outcomes
References: 1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
Hear from experts about how PFS is a surrogate for OS
Learn about the relevance of PFS data for predicting long-term patient outcomes
References: 1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
Learn about the relevance of PFS data for predicting long-term patient outcomes
Explaining the need to improve the outcome of 1L DLBCL treatment
References: 1. Shi Q, et al. J Clin Oncol. 2018;36:2593-602.
Explaining the need to improve the outcome of 1L DLBCL treatment
Key efficacy data from the POLARIX trial explained
References: 1. Tilly H, et al. N Engl J Med. 2022;386:351-63. 2. US FDA. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Guidance for Industry. 2018. 3. Shi Q, et al. J Clin Oncol. 2018;36:2593-602.
